BMO Capital raised the firm’s price target on Neurocrine (NBIX) to $147 from $124 and keeps a Market Perform rating on the shares after its Q3 results. The full path planning for Ingrezza erosion has not been laid yet, but following another strong quarter of Crenessity sales, BMO can see positive green-shoots that may start to solve some more urgent issues, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $179 from $175 at Piper Sandler
- Neurocrine price target raised to $164 from $160 at Canaccord
- Neurocrine price target raised to $203 from $175 at Citi
- Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Neurocrine Biosciences Reports Strong Q3 2025 Growth